网状Meta分析:生物制剂和小分子药物在克罗恩病诱导和维持缓解中的疗效比较
该网状Meta分析纳入39项3期随机对照试验,比较不同先进疗法对克罗恩病患者临床和内镜缓解的诱导与维持疗效。结果显示,英夫利西单抗联合硫唑嘌呤在诱导和维持临床缓解中排名最高,古塞奇尤单抗在维持内镜缓解中排名最高。新型IL-23抑制剂和抗TNF药物在诱导临床和内镜缓解中排名靠前。
要点
- 英夫利西单抗联合硫唑嘌呤在诱导和维持临床缓解中排名最高。
- 古塞奇尤单抗在维持内镜缓解中排名最高。
- 各疗法在维持临床缓解方面无统计学显著差异。
核心结论
- 新型IL-23抑制剂(如米吉珠单抗、瑞莎珠单抗和古塞奇尤单抗)和抗TNF药物(如英夫利西单抗和阿达木单抗)在诱导临床和内镜缓解中排名靠前。
- 这突显了新型先进疗法在克罗恩病中的潜力。
研究设计与样本
- 检索截至2025年1月的文献,纳入与安慰剂或活性对照比较的3期随机对照试验,共39项研究。
- 采用频率学方法进行网状Meta分析。
主要发现
- 临床缓解诱导分析中,英夫利西单抗联合硫唑嘌呤排名最高(93.2%),其次是古塞奇尤单抗(88.6%)和阿达木单抗(76.9%)。
- 古塞奇尤单抗在诱导临床缓解方面优于大多数干预措施。
- 临床缓解维持中,英夫利西单抗联合硫唑嘌呤排名最高(75.7%),其次是米吉珠单抗(71.8%)和古塞奇尤单抗(71.5%);各疗法在维持临床缓解方面无统计学显著差异。
- 内镜缓解诱导中,乌帕替尼排名最高(88.5%),其次是瑞莎珠单抗(73.7%)和古塞奇尤单抗(73.4%)。
- 内镜缓解维持中,古塞奇尤单抗排名最高(74%),其次是阿达木单抗(67%)和米吉珠单抗(64%)。
关键数值与推荐
- 主要终点为临床缓解(克罗恩病活动指数[CDAI] < 150分)的诱导和维持。
- 次要终点包括内镜缓解(克罗恩病简化内镜评分[SES-CD] ≤ 4或克罗恩病内镜严重程度指数[CDEIS] ≤ 4)的诱导和维持。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advances in medical management of Crohn's disease (CD) have transformed therapeutic goals. Clinical and endoscopic remission are important endpoints. AIM: To compare the efficacy of different advanced therapies in patients with CD. METHODS: We performed a literature search up to January 2025. We included phase 3 randomised controlled trials (RCTs) against placebo or an active comparator. The primary endpoint was induction and maintenance of clinical remission (CD Activity Index [CDAI] < 150 points). Secondary endpoints included induction and maintenance of endoscopic remission (Simple Endoscopic Score for CD (SES-CD) of ≤ 4 or CD Endoscopic Index of Severity (CDEIS) of ≤ 4). We performed network meta-analysis (NMA) using the Frequentist method. RESULTS: We included 39 studies. Induction of clinical remission analysis showed that infliximab combination with azathioprine ranked highest (93.2%), followed by guselkumab (88.6%) and adalimumab (76.9%). Guselkumab was superior to most interventions in inducing clinical remission. In maintenance of clinical remission, combination of infliximab and azathioprine ranked highest (75.7%) followed by mirikizumab (71.8%) and guselkumab (71.5%). There was no statistically significant difference between therapies in maintaining clinical remission. In induction of endoscopic remission, upadacitinib (88.5%) ranked highest, followed by risankizumab (73.7%) and guselkumab (73.4%). Guselkumab (74%) ranked highest in maintaining endoscopic remission, followed by adalimumab (67%) and mirikizumab (64%). CONCLUSION: Novel IL-23 inhibitors (such as mirikizumab, risankizumab and guselkumab) and anti-TNFs (such as infliximab and adalimumab) ranked high in the induction of clinical and endoscopic remission. This highlights the potential of novel advanced therapies for CD.
引用
- Shehab M, Alrashed F, Alrashidi A, et al. Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease. Aliment Pharmacol Ther. 2025. PMID: 40717455. doi:10.1111/apt.70295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。